Targeting Microglia to Treat Degenerative Eye Diseases

Microglia have been implicated in many degenerative eye disorders, including retinitis pigmentosa, age-related macular degeneration, glaucoma, diabetic retinopathy, uveitis, and retinal detachment. While the exact roles of microglia in these conditions are still being discovered, evidence from anima...

Full description

Bibliographic Details
Main Authors: Cepko, C.L (Author), Wang, S.K (Author)
Format: Article
Language:English
Published: Frontiers Media S.A. 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 02479nam a2200529Ia 4500
001 10-3389-fimmu-2022-843558
008 220420s2022 CNT 000 0 und d
020 |a 16643224 (ISSN) 
245 1 0 |a Targeting Microglia to Treat Degenerative Eye Diseases 
260 0 |b Frontiers Media S.A.  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.3389/fimmu.2022.843558 
520 3 |a Microglia have been implicated in many degenerative eye disorders, including retinitis pigmentosa, age-related macular degeneration, glaucoma, diabetic retinopathy, uveitis, and retinal detachment. While the exact roles of microglia in these conditions are still being discovered, evidence from animal models suggests that they can modulate the course of disease. In this review, we highlight current strategies to target microglia in the eye and their potential as treatments for both rare and common ocular disorders. These approaches include depleting microglia with chemicals or radiation, reprogramming microglia using homeostatic signals or other small molecules, and inhibiting the downstream effects of microglia such as by blocking cytokine activity or phagocytosis. Finally, we describe areas of future research needed to fully exploit the therapeutic value of microglia in eye diseases. Copyright © 2022 Wang and Cepko. 
650 0 4 |a age related macular degeneration 
650 0 4 |a carrier protein 
650 0 4 |a colony stimulating factor 1 
650 0 4 |a colony stimulating factor receptor 
650 0 4 |a complement component C1q 
650 0 4 |a cytokine production 
650 0 4 |a degenerative disease 
650 0 4 |a diabetic retinopathy 
650 0 4 |a eye disease 
650 0 4 |a fractalkine 
650 0 4 |a glaucoma 
650 0 4 |a human 
650 0 4 |a immunomodulation 
650 0 4 |a immunomodulation 
650 0 4 |a microglia 
650 0 4 |a microglia 
650 0 4 |a molecularly targeted therapy 
650 0 4 |a nerve degeneration 
650 0 4 |a nervous system inflammation 
650 0 4 |a neurodegeneration 
650 0 4 |a neuroinflammation 
650 0 4 |a neuroprotection 
650 0 4 |a nonhuman 
650 0 4 |a phagocytosis 
650 0 4 |a retina 
650 0 4 |a retina detachment 
650 0 4 |a retinitis pigmentosa 
650 0 4 |a Review 
650 0 4 |a somatomedin C 
650 0 4 |a therapies 
650 0 4 |a transforming growth factor beta 
650 0 4 |a uveitis 
700 1 0 |a Cepko, C.L.  |e author 
700 1 0 |a Wang, S.K.  |e author 
773 |t Frontiers in Immunology